Certified by Founder Lodge
Switch Therapeutics
United States - San Francisco, California
START UP
1 Disclosed Funding Rounds $52,000,000
0 Participating Investments
-
Founded date
2020
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Switch Therapeutics is an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science wi
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| March, 15 ,2023 | Series A | $52,000,000 |
Dolby Family Ventures
Upfront Ventures
BOLD Capital Partners
Eli Lilly and Company
Digitalis Ventures
FreeFlow Ventures
UCB Ventures
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
AIRRIVED | $6,100,000 | (Feb 4, 2026)
Derapi | $7,000,000 | (Feb 4, 2026)
Arbor(US) | $6,300,000 | (Feb 4, 2026)
Graici | $7,500,000 | (Feb 4, 2026)
enclaive | $4,849,418 | (Feb 4, 2026)